Diyabetes Mellitusta Toll-Like Reseptörlerin Rolü ve Ekspresyon Mekanizmaları

Akira S. Toll-like receptor signaling. Journal of Biological Chemistry, 2003, 278(40), 38105–38108.

Alexopoulou L, Holt AC, Medzhitov R, Flall RA. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature, 2001, 413(6857), 732–738.

Baccala R, Hoebe K, Kono DH, Beutler B, Theofilopoulos AN. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nature Medicine, 2007, 13(5), 543–551.

Benomar Y, Taouis M. Molecular mechanisms underlying obesity-induced hypothalamic inflammation and insulin resistance: pivotal role of resistin/TLR4 pathways. Frontiers in Endocrinology, 2019, 10, 140.

Caricilli AM, Picardi PK, de Abreu LL, Ueno M, Prada PO, Ropelle ER, et al. Gut microbiota is a key modulator of insulin resistance in TLR2 knockout mice. PLoS Biology, 2011, 9(12), e1001212.

Chen F, Zou L, Williams B, Chao W. Targeting toll-like receptors in sepsis: from bench to clinical trials. Antioxidants & Redox Signaling, 2021, 35(15), 1324–1339.

Chinnery HR, McLenachan S, Binz N, Sun Y, Forrester JV, Degli-Esposti MA, et al. TLR9 ligand CpG-ODN applied to the injured mouse cornea elicits retinal inflammation. American Journal of Pathology, 2012, 180(1), 209–220.

Dasu MR, Devaraj S, Park S, Jialal I. Increased toll-like receptor activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care, 2010, 33(4), 861–868.

Dasu MR, Devaraj S, Park S, Jialal I. High glucose induces toll-like receptor expression in human monocytes: Mechanistic insights. Diabetes, 2008, 57(11), 3090–3098.

Dasu MR, Jialal I. Free fatty acids and inflammation: Role of TLRs. Current Diabetes Reports, 2011, 11(1), 52–58.

Falck-Hansen M, Kassiteridi C, Monaco C. Toll-like receptors in atherosclerosis. International Journal of Molecular Sciences, 2013, 14(7), 14008–14023.

Fitzgerald KA, Kagan JC. Toll-like receptors and the control of immunity. Cell, 2020, 180(6), 1044–1066.

Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science, 2004, 303(5663), 1526–1529.

Jialal I, Kaur H. The role of Toll-like receptors in diabetes-induced inflammation: Implications for therapy. Endocrine Reviews, 2014, 35(4), 558–581.

Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nature Immunology, 2010, 11(5), 373–384.

Kawai T, Takahashi K, Sato S, Coban C, Kumar H, Kato H, et al. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nature Immunology, 2005, 6(10), 981–988.

Kim HS, Lee MS. Role of innate immunity in triggering and tuning of autoimmune diabetes. Current Molecular Medicine, 2009, 9(1), 30–44.

Kim JJ, Sears DD. TLR4 and insulin resistance. Gastroenterology Research and Practice, 2010, 2010(1), 212563.

Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annual Review of Immunology, 2002, 20, 709–760.

Kuzmich NN, Sivak KV, Chubarev VN, Porozov YB, Savateeva-Lyubimova TN, Peri F. TLR4 signaling pathway modulators as potential therapeutics in inflammation and sepsis. Vaccines, 2017, 5(4), 34.

Lee JY, Sohn KH, Rhee SH, Hwang D. Saturated fatty acids induce the expression of cyclooxygenase-2 mediated through TLR4. Journal of Biological Chemistry, 2001, 276(20), 16683–16689.

Lee J, Tian Y, Chan ST, Kim JY, Cho C, Ou JHJ. TNF-α induced by hepatitis C virus via TLR7 and TLR8 in hepatocytes supports interferon signaling via an autocrine mechanism. PLoS Pathogens, 2015, 11(5), e1004937.

Leon CG, Tory R, Jia J, Sivak O, Wasan KM. Discovery and development of toll-like receptor 4 antagonists: a new paradigm for treating sepsis and other diseases. Pharmaceutical Research, 2008, 25(8), 1751–1761.

Matziol T, Talagayev V, Weindl G, Wolber G. Structure-guided approaches to modulate endosomal TLR7, TLR8 and TLR9: advances, challenges and therapeutic promise. Drug Discovery Today, 2025, 104495.

Medzhitov R. Toll-like receptors and innate immunity. Nature Reviews Immunology, 2001, 1(2), 135–145.

Milanski M, Degasperi G, Coope A, et al. Saturated fatty acids produce an inflammatory response predominantly through the TLR4 pathway. Journal of Nutrition, 2009, 139(10), 1972–1977.

Piperi C, Goumenos A, Adamopoulos C, Papavassiliou AG. AGE/RAGE signalling regulation by miRNAs: associations with diabetic complications and therapeutic potential. International Journal of Biochemistry & Cell Biology, 2015, 60, 197–201.

Rasschaert J, Ladrière L, Urbain M, Dogusan Z, Katabua B, Sato S, et al. TLR3 and STAT-1 contribute to dsRNA + IFN-γ-induced apoptosis in primary pancreatic β-cells. Journal of Biological Chemistry, 2005, 280(40), 33984–33991.

Rogero MM, Calder PC. Obesity, inflammation, toll-like receptor 4 and fatty acids. Nutrients, 2018, 10(4), 432.

Sharma K, Ziyadeh F. Inflammatory mechanisms in diabetic nephropathy: Role of innate immunity pathways. Kidney International, 2019, 96(5), 1105–1120.

Sharma K, Ziyadeh F, Wang X. Toll-like receptors in diabetic kidney disease: Pathophysiology and therapeutic perspectives. Kidney Research and Clinical Practice, 2022, 41(1), 1–14.

Shi H, Kokoeva MV, Tzameli I. TLR4 links innate immunity and fatty acid-induced insulin resistance. Nature Medicine, 2006, 12(2), 156–163.

Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic complications. Korean Journal of Physiology & Pharmacology, 2014, 18(1), 1–14.

Suresh R, Mosser DM. Pattern recognition receptors in innate immunity, host defense, and immunopathology. Advances in Physiology Education, 2013, 37(4), 284–291.

Xie Z, Huang G, Wang Z, Luo S, Zheng P, Zhou Z. Epigenetic regulation of Toll-like receptors and its roles in type 1 diabetes. Journal of Molecular Medicine, 2018, 96(8), 741–751.

Yamamoto Y, Yamamoto H. Controlling RAGE to conquer diabetic vascular complications. Journal of Diabetes Investigation, 2012, 3(2), 107–114.

Yan SF, Ramasamy R, Schmidt AM. Advanced glycation end-products and their receptor in inflammation and diabetes complications. Nature Clinical Practice Endocrinology & Metabolism, 2008, 4(5), 285–293.

Yazıcı D, Sezer H. Insulin resistance, obesity and lipotoxicity. Obesity and Lipotoxicity, 2017, 277–304.

Yoneyama M, Kikuchi M, Matsumoto K, Imaizumi T, Miyagishi M, Taira K, et al. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. Journal of Immunology, 2005, 175(5), 2851–2858.

Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature, 2011, 469(7329), 221–225.

Zhu Z, Peng X, Li X, Tu T, Yang H, Teng S, et al. HMGB1 impairs endothelium-dependent relaxation in diabetes through TLR4/eNOS pathway. FASEB Journal, 2020, 34(6), 8641–8652.